PDCD1 and neoplasm: Immunotherapies that seek to preserve or restore the effector function of anti-tumor T cells have found the PD-1 immune checkpoint pathway to be an appropriate target because these expression patterns lay the scene for suppression of PD-1 +tumor-infiltrating lymphocytes (TIL) [52].